Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.5K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.9K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Standard-Based Port-Sharing Workflow for Simultaneous Robot-Assisted Distal Gastrectomy and Right-Sided Colectomy: A Case Report.

Surgical case reports·2026
Same author

Comprehensive Genomic and Transcriptomic Characterization of MTAP Loss Across Advanced Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Anaphylaxis and Fulminant Disseminated Intravascular Coagulation Due to Loxoprofen.

Internal medicine (Tokyo, Japan)·2026
Same author

Increasing plasma sodium with Tolvaptan under regulated water intake: comparison with hypertonic saline.

American journal of physiology. Renal physiology·2026
Same author

[A Case of Hepatic Oligometastasis from Distal Bile Duct Cancer Treated with Laparoscopic Surgery Five Years after Pancreatoduodenectomy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same author

Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.

Handbook of clinical neurology·2026

相关实验视频

Updated: Mar 31, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.0K

对于全身性红血性狼而言,非骨髓可塑性造血干细胞移植是不可行的.

Richard K Burt1, Ann Traynor, Laisvyde Statkute

  • 1Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA. rburt@northwestern.edu

JAMA
|February 2, 2006
PubMed
概括

自主非骨髓缩性造血干细胞移植 (HSCT) 为严重的系统性红斑狼 (SLE) 提供了有前途的治疗方法,该疾病对标准疗法不耐药. 这种方法在疾病活动和器官功能方面显著改善,五年生存率为84%.

更多相关视频

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K

相关实验视频

Last Updated: Mar 31, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.0K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.2K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.1K

科学领域:

  • 免疫学 免疫学 免疫学
  • 血液学 血液学 血液学
  • 类风湿病学 类风湿病学

背景情况:

  • 系统性红斑狼 (SLE) 是一种自身免疫性疾病,可以用免疫抑制剂治疗.
  • 一小部分SLE患者表现出耐火性疾病,尽管常规治疗.
  • 对于严重的,耐治疗的SLE,需要新的治疗策略.

研究的目的:

  • 评估强度免疫抑制与自身造血干细胞支持 (HSCT) 的安全性和有效性,在患有严重,耐火性SLE的患者中.
  • 评估结果,包括生存率,疾病活性和HSCT后的器官功能.

主要方法:

  • 一个单臂试验,涉及50名严重SLE耐标准治疗的患者.
  • 在干细胞调动和ex vivo丰富后,进行了自主非骨髓化的HSCT.
  • 治疗包括循环胺和马类抗细胞球蛋白,然后进行干细胞输液.

主要成果:

  • 48名患者完成HSCT;与治疗相关的死亡率为4% (2/50).
  • 总体5年生存率为84%,无病生存概率为50%.
  • 在SLE疾病活动指数 (SLEDAI),血清学标记 (ANA,anti-ds DNA) 和器官功能方面观察到显著改善.

结论:

  • 自主非骨髓缩性HSCT可以改善疾病活性,并改善治疗不耐治疗的SLE的器官功能.
  • 初步的非随机数据支持HSCT作为严重SLE的可行选择.
  • 在随机试验中进行进一步的调查是有必要的,以证实这些发现.